Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets.
Thrombocytopenia is a common condition in the critical care setting. Repetitive platelet transfusion might lead to formation of alloantibodies. HLA class I and human platelet antigen antibodies can lead to transfusion-refractory thrombocytopenia. Transfusion of cross-matched platelets often is effective in these patients. We report on the successful use of recombinant activated factor VII in an acute bleeding situation in a multi-transfused patient presenting with positive HLA class I alloantibody status and thrombocytopenia associated with platelet dysfunction refractory to even transfusion of cross-matched platelets. The 41-year-old female patient developed HLA class I antibodies during former episodes of massive transfusion. Her former medical history was empty concerning hemorrhagic events. During this specific bleeding episode the patient suffered from intractable profuse bleeding from the nasopharynx and oral cavity. Global coagulation tests were within the normal range. Platelet dysfunction was confirmed by PFA100. Initially the patient responded well to Desmopressin infusion, but after 36 h she became thrombocytopenic and refractory to even transfusion of cross-matched platelets. Recombinant activated factor VII was chosen as the last resort. Two identical boli of 160 microg/kg NovoSeven each were injected via a central line within an interval of 3 h. After the first injection bleeding was significantly reduced and vasopressor support discontinued. After the second bolus bleeding completely ceased and did not reoccur. We did not observe any side effects. The pluripotent hemostatic agent recombinant activated factor VII might be a new option in the treatment of hemorrhagic episodes in patients presenting with this rare disorder, especially when the patient is refractory to cross-matched platelets or matched platelets are not available.
Heuer
Lars
L
Department of Anaesthesiology, Intensive Care Unit, Klinikum Osnabrück GmbH, Am Finkenhügel 1, D-49076 Osnabrück, Germany. heuerlars@aol.com
Blumenberg
Detlef
D
D000328:Adult; D001791:Blood Platelet Disorders / Q000628:therapy*; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use; D019468:Disease Management; D005167:Factor VII / Q000627:therapeutic use; D015942:Factor VIIa; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006801:Humans; D007518:Isoantibodies / Q000097:blood*; D006472:Oral Hemorrhage / Q000188:drug therapy / Q000209:etiology*; D010979:Platelet Function Tests; D017713:Platelet Transfusion / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000627:therapeutic use; D016879:Salvage Therapy; D013921:Thrombocytopenia / Q000209:etiology*
D015395:Histocompatibility Antigens Class I; D007518:Isoantibodies; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa; D003894:Deamino Arginine Vasopressin